1 BTC
=
- USD
Viatris Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Viatris Inc. Common Stock
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Market Statistics
Trading Metrics
How to Buy VTRS
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy VTRS
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesThe global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key players are investing in R&D for improved formulations and expanding into emerging markets.
The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, including Phentolamine, MicroLine, GLK-302, and CorVision, alongside already-approved treatments like VUITY, QLOSI, VIZZ, and YUVEZZI.
Opus Genetics will present three abstracts at the ASCRS Annual Meeting in April 2026, including full results from Phase 3 studies evaluating phentolamine ophthalmic solution for presbyopia and mesopic vision disturbances. The company's partner Viatris is sponsoring an educational symposium on presbyopia management. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases and advancing phentolamine as a small-molecule therapy.
Viatris trades at a significant discount despite generating a 13.5% free cash flow yield and $2.2 billion in annual FCF. With a $650 million cost savings program launching in 2026, six regulatory decisions expected, and two Phase 3 assets with blockbuster potential, the stock trades 17% below peer-average EV/EBITDA. The company's differentiated specialty pipeline leverages its unmatched global distribution infrastructure across 40 countries and 165 markets, positioning it for genuine inflection in 2026 with projected first year of top-line growth since formation.
Over 120 pharmaceutical companies are actively developing 140+ pipeline drugs for systemic lupus erythematosus (SLE), with approximately 30+ drugs in mid-stage development and 85+ in early stages. Key players include Roche, Biogen, Novartis, AbbVie, and Johnson & Johnson, with promising therapies targeting various mechanisms such as B cell inhibitors, JAK inhibitors, and TLR antagonists. Recent regulatory milestones include FDA Fast Track designation for nipocalimab and Breakthrough Therapy Designation for litifilimab.
